Utility of Contrast-Enhanced Transabdominal Ultrasonography to Diagnose Early Chronic Pancreatitis
Table 1
Clinical characteristics of participants.
Control ()
Early chronic pancreatitis ()
Chronic pancreatitis ()
Age
61.5 (28–74)
66 (54–69)
58.5 (40–67)
0.0913
Sex (M : F)
5 : 1
5 : 2
8 : 0
0.2826
BMI (kg/m2)
21.4 (18.5–24.5)
21.2 (19.7–29.6)
20.8 (16.2–26.1)
0.9036
Body surface area (m2)
1.56 (1.47–1.92) ()
1.64 (1.44–1.70) ()
1.62 (1.51–1.79) ()
0.6105
PV/BSA (cm2/m2)
38.83 (36.67–42.56) ()
27.26 (18.94–46.38) ()
19.23 (7.48–38.42) ()
0.0879
Amylase (U/L)
100 (38–170)
105 (58–544)
66 (33–127)
0.1675
Lipase (U/L)
33 (27–52) ()
48 (32–132) ()
21 (10–121) ()
0.0564
LDL-cholesterol (mg/dL)
125 (56–155)
92 (60–99)
65 (40–127)
0.0901
Triglyceride (mg/dL)
74 (41–206)
122 (54–399)
72 (39–177)
0.2596
Serum CPR (ng/mL)
1.28 (0.47–2.53)
2.02 (0.17–2.74)
1.55 (0.23–3.17)
0.4047
HbA1c (%: NGSP)
5.7 (5.3–6.0) ()
5.9 (4.7–6.5) ()
8.5 (5.4–9.4) ()
0.0581
PFD test (%)
72.9 (69.6–75.4) ()
71.6 (60.2–78.0) ()
56.3 (18.7–72.7) ()
0.0474
Kruskal-Wallis test,
2
test. BMI: body mass index, BSA: body surface area, and PV: pancreatic volume. CPR: C-peptide immunoreactivity and PFD: pancreatic function diagnostant.